Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
ID: 351124Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351124

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-23-317.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for competing revisions to existing NIH single project research grants and cooperative agreements, with a focus on clinical trials. This initiative allows eligible organizations to apply for additional funding to expand ongoing projects under specific NIH Institutes or Centers, following the guidelines set forth in the Notice of Special Interest (NOSI). The application process is electronic, requiring submissions via the NIH ASSIST system or Grants.gov, and will be evaluated based on scientific merit, innovation, and relevance to NIH priorities. Interested applicants must submit their proposals by November 24, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further assistance.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-23-317.html
    The National Institutes of Health (NIH) is announcing a funding opportunity for revision applications to expand existing NIH single project research grants and cooperative agreements, particularly those related to clinical trials. The funding aims to allow organizations to apply for additional support to enhance ongoing projects under specified Institutes or Centers. This announcement, titled PA-23-317, follows several related Notices of Special Interest (NOSIs) that detail the eligibility and types of applications accepted. Eligible applicants include a wide range of organizations, from higher education institutions to non-profits and local governments. The application process is electronic, requiring submission via the NIH ASSIST system or Grants.gov. Review criteria will assess the significance, investigator qualifications, innovation, approach, and the environment of proposed projects. Final funding decisions will be based on scientific merit, relevance to NIH priorities, and available funds. The expiration date for applications is November 24, 2026, and applicants are urged to submit applications early to correct potential errors. This funding opportunity reflects NIH's commitment to advancing scientific research through collaborations and innovative project expansions.
    Similar Opportunities
    Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for organizations holding specific types of NIH grants to submit applications for changes in recipient organization status, known as Successor-in-Interest. This initiative aims to facilitate transitions for organizations while ensuring project continuity, allowing eligible applicants—including various higher education institutions, nonprofits, government entities, and foreign organizations—to propose research that aligns with the original NIH-supported project scope. Applications will undergo an administrative evaluation focusing on compliance with federal regulations, with key dates including an open submission period starting July 19, 2024, and a funding expiration date set for July 18, 2027. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced an urgent funding opportunity for competitive revisions to existing research grants aimed at addressing immediate public health crises. This initiative allows Principal Investigators holding specific NIH grants to apply for additional funding to meet unforeseen needs related to public health emergencies, with applications routed directly to the relevant NIH awarding component. The program emphasizes support for diverse institutions, including historically underrepresented entities, and aims to enhance research capacity in critical health areas. Interested applicants can find more details and submit inquiries via grantsinfo@nih.gov, with proposals due by October 25, 2025, under the funding opportunity announcement PA-23-044.
    Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for competitive revisions to support clinical trials in somatic cell genome editing, specifically under the funding opportunity RFA-RM-24-008. This initiative aims to expand the existing Somatic Cell Genome Editing program by soliciting applications from awardees with active U19 awards funded under RFA-RM-22-015, which previously did not allow clinical trials. The funding will facilitate first-in-human genome editing clinical trials, including essential preparatory activities such as patient recruitment, regulatory approvals, and the development of clinical trial designs. Interested applicants must submit their proposals by February 13, 2026, and can find additional information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a limited competition for the renewal of existing clinical trial cooperative agreement awards (U01) that require additional time and resources to complete ongoing research on neurological disorders. This funding opportunity is specifically aimed at supporting extramural research efforts and emphasizes the importance of collaboration between NIH and award recipients to achieve significant advancements in the field. Eligible applicants include various federal entities, independent school districts, and tribal organizations, with the application submission period opening on February 5, 2025, and deadlines extending throughout the year. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-149.html.
    Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for organizations seeking to change the recipient organization of specific NIH grants. This initiative allows eligible applicants, including higher education institutions, nonprofits, and various government entities, to submit applications for the transfer of grant awards, ensuring continuity in research projects. While the submission of applications does not guarantee approval for the transfer, the NIH encourages coordination with relevant institutes and adherence to grant policies to facilitate a smooth transition. Interested parties can find more information and submit inquiries via email at grantsinfo@nih.gov, with key submission dates starting from July 12, 2024, and the opportunity closing on July 12, 2027.
    Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced an Emergency Competitive Revision program aimed at providing funding for applications related to disasters declared under the Stafford Act or public health emergencies. This initiative is designed to support existing NIH awards and facilitate projects that address urgent public health issues stemming from such emergencies. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and local governments, particularly those impacted by recent disasters. The funding opportunity, designated as PA-24-201, opens on April 19, 2024, with applications due by April 18, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PA-24-201.html.
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants," aimed at accelerating the clinical validation of biomarker assays for cancer detection, diagnosis, prognosis, and treatment response. This initiative encourages multidisciplinary collaboration among researchers, clinicians, and statisticians, focusing on assays that have nearly completed analytical validation and utilize human specimens. The funding amount is capped at $150,000 per year for a maximum duration of three years, with application deadlines starting from January 14, 2025, and concluding on October 15, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at validating biomarker assays developed through NIH-supported research grants, specifically under the R01 mechanism, with a focus on enhancing their clinical application for cancer detection and treatment. This initiative seeks to accelerate the translation of molecular, cellular, and imaging markers into clinical settings, encouraging multidisciplinary collaborations among scientists, clinicians, and laboratory experts to adapt and validate these biomarkers for various cancer-related purposes. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with funding available up to $150,000 for a project period of up to three years. Interested parties should note that the application deadline is October 13, 2026, and can find further details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Research Project Grant (Parent R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant, designated as the Parent R01 Clinical Trial Required (Funding Opportunity Number PA-25-305). This grant supports discrete research projects that include at least one clinical trial and align with the scientific missions of participating NIH Institutes and Centers. The initiative aims to foster innovative health-related research and enhance scientific resources, with applications accepted from a diverse range of organizations, including higher education institutions and community-based organizations. Applications will open on January 5, 2025, with subsequent submission deadlines throughout 2025 and 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the continuation or revision of clinical trials under the National Institute of Dental and Craniofacial Research (NIDCR) through a UH3 Exploratory/Developmental Cooperative Agreement. This initiative aims to support competing renewals or competitive revisions of ongoing clinical trials that focus on dental, oral, and craniofacial health, emphasizing the importance of structured data generation in advancing healthcare research. Eligible applicants include a wide range of institutions, such as public and private entities, nonprofits, and government organizations, with the application deadline set for January 6, 2028. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries regarding the application process.